SQZ-622(Novartis Pharma)

N/A

Report date: 2026/03/19 17:22:27

Base Information

Drug NameSQZ-622(Novartis Pharma)

Drug Alias NameSQZ-622

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionInterleukin-3 receptor subunit alpha modulatorsT cell surface glycoprotein CD3 modulators

TargetsInterleukin-3 receptor subunit alphaT cell surface glycoprotein CD3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A